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Background: Patients with Cystic Fibrosis are prone to develop sinonasal disease. Studies in genotype–phenotype correlations for sinonasal
disease are scarce and inconclusive.
Methods: In this observational study several aspects of sinonasal disease were investigated in 104 adult patients with CF. In each patient a disease
speciﬁc quality of life questionnaire (RSOM-31), nasal endoscopy and a CT scan of the paranasal sinuses were performed. Patients were divided
into two groups, class I–III mutations and class IV–V mutations, based on their CFTR mutations.
Results: The prevalence of rhinosinusitis in adult patients with CF was 63% and the prevalence of nasal polyps 25%. Patients with class I–III
mutations had signiﬁcantly smaller frontal sinuses, sphenoid sinuses, more opaciﬁcation in the sinonasal area and more often osteitis/
neoosteogenesis of the maxillary sinus wall compared to patients with class IV and V mutations.
Conclusion: These data suggest more severe sinonasal disease in patients with class I–III mutations compared to patients with class IV–V
mutations.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Rhinosinusitis; Nasal polyps; Genotype1. Introduction
Cystic Fibrosis (CF) predisposes a patient to pathology of the
nose and the paranasal sinuses. The mucosa lining the nose and
paranasal sinuses is similar to the mucosa of the lower airways.
Therefore pathology in both compartments of the respiratory
system is expected to be quite identical. In the sinonasal system
the CF distinctive viscous mucous results in impaired ciliary☆ Part of this work has been presented at the 35th European Cystic Fibrosis
Conference, June 6–9, Dublin, Ireland, 2012 as an oral presentation “Sinonasal
pathology in adult patients with Cystic Fibrosis” J Cyst Fibros 2012 suppl
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http://dx.doi.org/10.1016/j.jcf.2013.10.011function, mucous stasis and consequently bacterial superinfec-
tion. Moreover, research showed other factors are associated
with the tendency of CF patients to develop sinonasal disease.
Evidence suggests that heterozygotes for the Cystic Fibrosis
Transmembrane Regulator (CFTR) mutation are predisposed to
develop chronic rhinosinusitis compared to the normal wild-
type CFTR population (1,2). This might indicate a direct
influence of the CFTR mutation in the aetiology of CF sinonasal
disease. Another factor that might play a role in the development
of sinonasal disease in CF is the environment of the sinuses.
Research showed that the immune response in the sinuses is
weak, bioavailability of antibiotics is low and the environmental
conditions increases antibiotic-resistance of pathogens in the
sinuses (3). Altogether this may result in chronic and recalcitrant
rhinosinusitis in patients with CF.by Elsevier B.V. All rights reserved.
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patient's quality of life (1,4). Moreover pathogens from the
sinuses can migrate to the lungs and cross-infect the lungs (3,5).
Often the upper airways barely receive attention in the routine
care of the CF patient. Especially in adult patients the upper
respiratory tract is not regularly examined. Therefore the actual
impact of sinonasal disease in adult patients cannot be estimated
properly.
Since the identification of the CF mutation in 1989 approx-
imately 1939 different mutations have been described (6).
These mutations can be classified according to their impact on
the function of the Cystic Fibrosis Conductance Transmem-
brane Regulator (CFTR) protein. Class I–III mutations are
associated with a severe phenotype of CF. Mutations in class
IV–V are associated with a milder CF phenotype (7).
Considerable amount of studies have been performed to find a
correlation between the genotype and the phenotype of CF (7,8).
Correlations between genotype and phenotype were found for
pancreatic function, lung function, age at diagnosis, nutritional
status and Pseudomonas aeruginosa colonisation (8,9).
Research in a genotype–phenotype correlation for sinonasal
disease is scarce and the results are inconclusive. Jorissen and
co-workers showed ΔF508 homozygosity was a risk factor for
paranasal sinus disease in CF (10). Other investigators showed
nasal polyps were more frequent in patients with the genotype
consisting of both ‘strong’ mutations compared to patients with
a genotype consisting of unknown or ‘mild’ mutations (11).
However, no association between sinonasal disease and genotype
was found in the study of Cimmino et al. (12). Moreover, with
their research Sakano et al. displayed no association with the
pathology seen on a sinus CT scan and the severity of CF (13). In
summary, the current data of a possible genotype–phenotype
correlation for sinonasal disease remain inconsistent. Investigating
genotype–phenotype correlations can lead to more knowledge on
the pathogenesis of sinonasal disease in Cystic Fibrosis. To date
this pathophysiology is poorly understood. Besides, a possible
correlation can have clinical implications.
In the present prospective study several aspects of sinonasal
disease were examined and correlated with genotype in a large
group of adult patients with CF.
2. Study design
2.1. Patients
Adult patients who regularly attend the Cystic Fibrosis
centre of the Haga Teaching Hospital were studied. All subjects
with a diagnosis of CF, based on a positive sweat test and/or
genotype were considered eligible for this study. The intention
was to include 100 patients. The present study was performed
from April 2011 to February 2012 and was approved by the
local medical ethics committee.
2.2. Genotype
Patients were divided in two groups; subjects with class I–III
mutations and patients with class IV–V mutations. Subjectswho were homozygous or compound heterozygous for class I–
III mutations were allocated to the class I–III mutation group
and patients who carried at least one class IV–V mutation were
addressed to the class IV–V mutation group. In patients where
one or two CFTR mutations were unknown the sweat test was
used to confirm the diagnosis of CF. In those patients pancreatic
function and age at diagnosis were used to allocate patients to
one of the two groups. Pancreatic function is known to correlate
well with genotype (8). Moreover age at diagnosis correlates
with genotype as well (9,14). Considering the age at diagnosis a
cut-off value of 10 years was used in this study. A subject that
was pancreatic sufficient and the age at diagnosis was N10 years
was considered as carrying a class IV–V mutation. Pancreatic
insufficiency and age at diagnosis b10 years was considered
among the class I–III mutation group.
2.3. Rhinosinusitis and nasal polyps
In this study rhinosinusitis is defined as an inflammation of the
nose and paranasal sinuses characterised by two or more of
the following symptoms: nasal blockage/congestion/obstruction,
nasal discharge (anterior or posterior), facial pain/pressure and/or
a reduction or loss of smell. One of them should be either
nasal blockage/congestion/obstruction or nasal discharge. Along
with these symptoms either endoscopic signs of nasal polyps,
mucopurulent discharge primarily from the middle meatus,
oedema/mucosal obstruction primarily in the middle meatus and/
or mucosal changeswithin the ostiomeatal complex and/or sinuses
on a CT-scan had to be present (1). In the present study symp-
toms are measured with the Rhinosinusitis Outcome Measure
(RSOM-31). Since this RSOM is a quality of life questionnaire
each symptom was scored on a 6-point Likert scale. A symptom
was included in the definition of rhinosinusitis when subjects rated
the symptom with a 2 (‘mild or slight problem’) or more.
The presence of nasal polyps was defined as an endoscop-
ically visualised grape-like lesions in at least one nasal cavity
following a decongestant (xylometazoline 0.1%).
2.4. Quality of life
Disease specific quality of life (QoL) was measured with the
‘Rhinosinusitis Outcome Measure’ (RSOM-31)(15). This validat-
ed questionnaire consists of 31 items on rhinosinusitis and each
item is scored on a ‘Magnitude Scale’ and an ‘Importance Scale’.
Since previous experience showed that patients had difficulties in
distinguishing between the ‘Magnitude Scale’ and the ‘Importance
Scale’, in the present study only the ‘Magnitude Scale’ was
measured (J Piccirillo personal communication). The RSOM-31
contains seven domains: nasal, eye, sleep, ear, general, practical
and emotional. Disease specific QoL was analysed from the total
score on the RSOM-31 divided by the number of completed items,
resulting in a ‘mean per item’ (range 0–5, with higher scores
representing a worse quality of life). Since the RSOM-31 contains
pulmonary symptoms such as cough and dyspnea, the disease
Cystic Fibrosis can influence the outcome of this questionnaire.
Therefore the nasal domain of the RSOM-31 was analysed
separately.
Table 1






N = 31 N = 73
Mean age, years (SD) 40.5 (10.7) 32.4 (10.4) 0.000 ⁎
Male, n (%) 14 (45.2) 41 (56.2) 0.304
Previous sinus surgery, n (%) 19 (61.3) 40 (54.8) 0.541
Lung function:
Mean FEV 1% predicted (SD) 66.3 (25.4) 62.1 (25.5) 0.389
Mean FVC % predicted (SD) 87.5 (18.1) 83.0 (19.0) 0.265
Oral steroids (%) 1 (3.2) 9 (12.3) 0.150
Nasal steroids (%) 9 (29.0) 32 (43.8) 0.158
⁎ p-Value b 0.05.
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Computed tomography of the paranasal sinuses was per-
formed (Toshiba Aquilion 16). Patients were situated with their
head tilted backwards until the palatum durum was positioned
perpendicular to the bench. Axial computed tomography was
performed with a slice thickness of 0.5 mm and images were
reconstructed at 1.0 mm. The scan ranged from the upper
border of the frontal sinuses to the lower part of the teeth in the
maxilla. No intravenous contrast was used.
Paranasal sinus opacification was assessed using the Lund–
Mackay score (L–M score). This validated staging system
grades every sinus as 0: normal, 1: partial opacification or 2:
total opacification. These points are applied to the maxillary,
anterior ethmoid, posterior ethmoid, sphenoid and frontal sinus
on each side. The ostiomeatal complex is graded as 0: patent or
1: occluded. The Lund–Mackay score ranges from 0–24. Since
CF patients often display aplasia of one or more sinuses the
Lund–Mackay score had to be adjusted for this study. The
absence of one or more sinuses distort the L–M scores and
makes comparison between patients incorrect. Therefore the
total L–M score was divided by the amount of developed
sinuses or components of the sinonasal system, resulting in a
L–M score per component of the sinonasal system. This ad-
justed L–M score ranged from 0–2. An experienced radiologist
(C.J.v.R) analysed all CT-scans and was blinded for genotype
and previous study results of the patients.
The volume of the sinuses were analysed with an Aquarius
Intuition software (TeraRecon®). For each sinus the circumfer-
ence on each slice was drawnmanually and the total volume of the
sinus was calculated subsequently. Volumes of the left and right
sides were added up. Only the frontal, sphenoid and maxillary
sinuseswere measured. Aplastic sinuses were calculated as 0 cm3.
Moreover increased bone density and irregular thickening,
in this study called ‘osteitis/neoosteogenesis’, of the maxillary
sinus wall was evaluated and graded as 0: absent, if both
maxillary sinuses did not show osteitis/neoosteogenesis and as
1: present, if one of the maxillary sinuses showed signs of
osteitis/neoosteogenesis.
Finally the anatomy of the ostiomeatal complex (OMC) was
evaluated. Both left and right OMCwere assessed. The anatomy
of the OMC was scored as 0: normal on both sides, 1: abnormal
anatomy on one or both sides due to sinus surgery in the past or
2: abnormal anatomy on one or both sides without sinus surgery
in the past. To ascertain if patients had sinus surgery in the past,
surgery reports were requested. In case no surgery reports were
available, one experienced otorhinolaryngologist (E.R.), whom
was ignorant to previous data of the patients, evaluated the scan
and assessed if the patients had surgery on the OMC.
2.6. Data and statistics
Data in this study were analysed with SPSS for Windows,
version 17.0. The aspects of sinonasal disease were reported by
descriptive characteristics such as mean, standard deviation (SD)
and percentage. To determine whether the proportion in the study
group takes a particular value (from literature) a z test for aproportion was used. For every aspect of sinonasal disease a
comparison between patients with class I–III mutations and
patients with class IV–V mutations was made. A chi-squared
analysis was applied to rhinosinusitis, nasal polyps and osteitis of
the maxillary sinus wall. The RSOM-scores, PSV of the frontal
and sphenoid sinuses were analysed using a non-parametric test.
The L–M scores and PSV of the maxillary sinuses were analysed
using parametric tests. A p-value of b0.05 was considered
statistically significant. Since nine hypothesis tests were per-
formed on one population the data had to be corrected for multiple
testing. In this study a Holm–Bonferroni correction was applied.
3. Results
3.1. Patients
One hundred and twenty three patients were invited to
participate in this study, of which 104 gave informed consent
and were included. The mean age of all 104 subjects was
34.8 years (SD: 11.1) and the percentage of male subjects was
52.9%. Fifty-nine patients (56.7%) reported a history with one
or more surgeries in the sinonasal area. In total 10 patients were
on oral steroids and 41 patients on nasal steroids during the
study. The descriptive statistics of the subjects separated for the
different mutation classes are displayed in Table 1. This table
shows the mean age of patients with class IV–V mutations was
significantly higher than the mean age of patients with class
I–III mutations (p–value b 0.001). All other descriptive param-
eters did not differ significantly between the two groups.
3.2. Genotype
In 3 patients one CFTR mutation was unknown and in one
patient both of the CFTR mutations were unknown. Table 2
shows the distribution of the genotypes among the 104 study
patients. The last column states to which group the patients
were assigned. The characteristics of the 3 patients with one
unknown mutation are displayed in Table 2. One of the three
patients was assigned to the class I–III mutation group and 2
were allocated to the IV–V mutation group. The subject with
both unknown mutations was diagnosed at 42 years, but was
Table 3
Aspects of sinonasal disease divided for severity of CF.





N = 31 N = 73
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patient had typical characteristics of ‘mild disease’ he was
assigned to the class IV–V mutation group. In total 73 subjects
were allocated to the class I–III mutation group and 31 to the
class IV–V mutation group.Rhinosinusitis; N (%) 16 (51.6) 49 (67.1) 0.135
Nasal polyps; N (%) 5 (16.1) 21 (28.8) 0.173
RSOM-31 total score; mean (SD) 1.21 (0.77) 1.15 (0.66) 0.672
RSOM-31 nasal domain; mean (SD) 1.44 (0.97) 1.51 (0.85) 0.536
L–M score per component a; mean (SD) 0.62 (0.41) 0.85 (0.32) 0.007 ⁎
PSV frontal sinuses b (cm3); mean (SD) 5.09 (5.00) 2.34 (2.96) 0.002 ⁎
PSV sphenoid sinuses b (cm3); mean (SD) 3.79 (4.58) 1.74 (2.18) 0.000 ⁎
PSV maxillary sinusesb (cm3); mean (SD) 18.83 (8.42) 17.17 (7.70) 0.331
Osteitis maxillary sinuses; N (%) 21 (67.7) 67 (91.8) 0.002 ⁎
a Lund–Mackay score per component of sinonasal system.
b PSV = Paranasal sinus volume.
⁎ Statistically significant after Holm–Bonferroni correction.3.3. Rhinosinusitis and nasal polyps
Sixty-five patients (62.5%) met the EPOS criteria of the
definition of rhinosinusitis. This is significantly higher (p-value b
0.0001) than the 10.9% of chronic rhinosinusitis observed in
the general population (16). Table 3 shows the percentage of
rhinosinusitis in patients with class I–III mutations was slightly
higher than in patients with class IV–V mutations, but the
difference was not statistically significant (p-value = 0.14).
In 26 patients (25.0%) nasal endoscopy showed nasal polyps
on one or both sides. This observed prevalence is significantly
higher (p-value b 0.0001) than the 2.4% observed in the gen-
eral population (17). Of the 26 CF patients with nasal polyps
21 carried class I–III mutations and 5 class IV–V mutations
(p-value = 0.17).Table 2
Distribution of genotypes and their mutation classes.
Genotype Frequency; N (%) Class of mutation
F508del/F508del 61 (58.7) I–III
F508del/3849 + 10kbC 2 (1.9) IV–V
F508del/N1303K 2 (1.9) I–III
F508del/R1162X 2 (1.9) I–III
F508del/A455E 12 (11.5) IV–V
F508del/3272-26A N G 5 (4.8) IV–V
F508del/E528X 1 (1.0) I–III
F508del/S1251N 3 (2.9) IV–V
F508del/R75Q 1 (1.0) IV–V
F508del/G542X 2 (1.9) I–III
F508del/1717-1G N A 1 (1.0) I–III
F508del/Ser489X 1 (1.0) I–III
F508del/4382delA 1 (1.0) − a
F508del/L1077 1 (1.0) I–III
F508del/1813insC 1 (1.0) − b
A455E/S1251N 1 (1.0) IV–V
A455E/E60X 1 (1.0) IV–V
3272-26A N G/G970R 1 (1.0) IV–V
3272-26A N G/R1162X 1 (1.0) IV–V
F508del/UNK 2 (1.9) − c
R117H-7T/UNK 1 (1.0) − d
UNK/UNK 1 (1.0) - e
Total 104 (100.4)
One patient with pancreatic sufficiency and diagnosed at 46 years of age (class
IV–V).
a Patient with pancreatic sufﬁciency and diagnosed at 19 years of age (class
IV–V).
b Patient with pancreatic insufﬁciency and diagnosed at 9 years of age (class
I–III).
c One patient with pancreatic insufﬁciency and diagnosed at 4 years of age
(class I–III).
d Patient with pancreatic sufﬁciency and diagnosed at 39 years of age (class
IV–V).
e Patient with pancreatic insufﬁciency secondary to chronic pancreatitis and
diagnosed at 42 years of age (class IV–V).3.4. Quality of life (RSOM-31)
The mean total score on the RSOM-31 of the total study
population was 1.17 (SD: 0.70). The mean score on the nasal
domain was 1.49 (SD: 0.88). Table 3 displays the RSOM
scores for the two groups based on mutation classes. Statistical
analyses showed no significant difference between these two
groups for the total score and the nasal domain (p-value = 0.67,
respectively p-value = 0.54).
3.5. Computed tomography
Of the study population 15 patients showed aplasia of both
frontal sinuses (20.0% class IV–V, 80.0% class I–III). Eight
patients had one aplastic frontal sinus (12.5% class IV–V, 87.5%
class I–III). Moreover two patients displayed aplasia of one
sphenoid sinus (both with class I–III mutations). In one patient
very extensive sinus surgery leads to indistinct boundaries of the
sinuses and therefore this patient was not included in the analysis
of the L–M scores. This patient was carrying two class I–III
mutations.
The mean L–M score per component of the sinonasal
system for 103 patients was 0.78 (SD: 0.37). Table 3 shows the
L–M scores in patients with class I–III mutations were sig-
nificantly higher compared to patients with class IV–V muta-
tions (p-value = 0.007).
Paranasal sinus volume was analysed in all 104 patients. The
mean volume of the left and right frontal sinuses together was
3.16 cm3 (SD: 3.87). For the sphenoid sinuses the mean volume
was 2.35 cm3 (SD: 3.21). The mean volume of both maxillary
sinuses together was 17.66 cm3 (SD: 7.92). Table 3 presents the
volumes of these sinuses for patients with class IV–Vmutations
and class I–III mutations. The frontal sinuses and the sphenoid
sinuses of patients with class I–III mutations were significantly
smaller compared to patients with class IV–V mutations
(p-value = 0.002, respectively p-value = 0.000).
Among the study population 88 patients (84.6%) had signs of
osteitis/neoosteogenesis in one or two maxillary sinuses. This
percentage was significantly higher in the group of patients with
a)
b)
Fig. 1. a) Abnormal anatomy of uncinate process on right side, normal anatomy
on left side. b) Bilateral abnormal anatomy of uncinate process.
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mutations (p-value = 0.002, Table 2).
Analysis of the ostiomeateal complex showed a normal
anatomy on both sides in 43 patients (41.3%), an abnormal
anatomy on one or both sides with sinus surgery in the past in 45
patients (43.3%). In 16 patients (15.4%) the CT-sinus showed
an abnormal anatomy of the ostiomeatal complex without any
reported sinus surgery in the past or without signs of previous
sinus surgery on the CT-scan. This abnormal anatomy often
involved the uncinate process, where this process was projected
medially instead of laterally (Fig. 1a and b).
4. Discussion
The sinonasal system is gradually receiving more attention in
the treatment of the multi-organ disease Cystic Fibrosis.
Pathology of the nose and the paranasal sinuses in CF patients
have been observed previously. Only recently more substantial
research in this area was initiated. Where previous studies
include a rather heterogeneous study population with children
and adults with CF, the present study focuses on a large group of
only adult patients.
Table 1 showed the characteristics of the two groups were
almost comparable. However, the mean age differed signifi-
cantly, with a higher mean age in the patients with class IV–V
mutations. One could speculate this is the result of the fact that
class IV–V mutations often leads to a higher life expectancy.
For this reason the group of patients with class IV–V mutations
contained relatively older patients compared to the group of
patients carrying class I–III mutations.
Since CF predisposes a patient to rhinosinusitis, the high
prevalence of this complication was expected. In total 65
patients fulfilled the criteria of the EPOS for rhinosinusitis. This
prevalence among CF patients is considerably higher compared
to the prevalence in the general population. However, the
prevalence in the general population from the GA2LEN study
was the prevalence of chronic rhinosinusitis. One limitation of
this study is that the time aspect of the rhinosinusitis in the study
population is unknown. Where in the GA2LEN study was asked
for symptoms N12 weeks in the previous 12 months, we only
asked for symptoms in the last 2 weeks. Therefore one might
suggest that these two prevalences cannot be compared to each
other, although considering the CT-scans of these patients, a
chronic course of this rhinosinusitis is suspected. The investi-
gators feel the high prevalence of rhinosinusitis and nasal polyps
among adult patients with CF should indicate a closer follow-up
of this pathology by the pulmonary physician as well as the
otorhinolaryngologist.
In the present study we chose to use a ‘mean per item’ outcome
of the RSOM-31 to ensure we could include the incomplete
questionnaires in the analyses. However, this method is not
previously used in other studies. To compare data of CF patients
with data of patients suffering from chronic rhinosinusitis (CRS),
we could calculate ‘mean per item’ scores in other studies. For the
study of Dietz de Loos and colleagues (18) this calculated mean
total RSOM score in patients with CRS and nasal polyps was 2.13
and for patients with CRS without nasal polyps this was 2.16.Compared to our results of 1.21 and 1.15 for the class IV–V
mutation group and the class I–III mutation group, respectively,
the reported symptoms of CF patients were lower. Results of
Hissaria et al. confirm this observation with a mean total RSOM
score of 2.2 in patients with sinonasal polyposis (19). This could
suggest that CF patients tend to underestimate the rhinosinusitis
symptoms. One could speculate this is explained by amore chronic
or perhaps congenital course of rhinosinusitis in CF patients or this
could be due to other pathology, for example pulmonary and
gastrointestinal disease, that outweigh sinonasal disease.
In this study we used a modified Lund–Mackay score. Since
many CF patients display aplasia of the frontal sinuses, the
original L–M scoring system cannot be used accurately in these
patients. Therefore the investigators chose to use an adjusted
L–M score, the L–M score per component of the sinonasal
system. For this reason comparison with literature required
adaptation of the data. Dietz de Loos et al. showed a mean L–M
score of 18 in 137 patients with CRS and nasal polyps and a
mean score of 5 in 97 patients with CRS but no nasal polyps
(18). Corrected for the 4% of the general population with two
aplastic frontal sinuses (20), the L–M score per component of
the sinonasal system would be 1.51 for patients with CRS and
nasal polyps and for patients with CRS without nasal polyps
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intermediate of those two CRS subpopulations of 0.78.
In our study patients with class I–III mutations had sig-
nificantly smaller frontal and sphenoid sinuses compared to
patients with class IV–V mutations. For the maxillary sinuses
this difference did not reach statistical significance. These
findings were supported by several studies (20–23). To date the
exact pathogenesis of abnormal paranasal sinus development is
unknown. A commonly held hypothesis is that chronic sinusitis
during development decreases sinus pneumatization, leading to
smaller sinuses (20). Considering this hypothesis, one could
speculate patients with class I–III mutations develop chronic
sinusitis earlier in life compared to patients carrying class IV–V
mutations. Consequently, pneumatization is reduced or not even
initiated, resulting in hypoplastic or aplastic sinuses respective-
ly. The fact that the maxillary sinus is relatively well developed
and no difference between the two study groups was detected,
could be explained by the timing of pneumatization. The
maxillary sinuses pneumatize prenatally, while the frontal and
sphenoid sinuses develop after birth. Since sinusitis can only
develop postnatal, it can interfere with the pneumatization of the
frontal and sphenoid sinuses more compared to pneumatization
of the maxillary sinus. Interestingly, Chang et al. contradict the
previous hypothesis and state that sinus hypoplasia precedes
sinus infection in a porcine model of CF. They suggest a direct
influence of the CFTR protein on sinus development (24). The
residual CFTR function in patients with class IV–V mutations
as opposed to no CFTR function in the class I–III mutation
group could explain our observation of smaller sinuses in severe
CF. The volume of the ethmoid sinus was not analysed in this
study, since this was technically difficult. Where the other
sinuses had distinct boundaries to draw a circumference, the
ethmoid sinus has less distinct boundaries. For this reason only
opacification of the ethmoid sinuses was evaluated. Like the
maxillary sinus the ethmoid sinus pneumatizes prenatally. None
of the patients showed aplastic ethmoid sinuses, however the
investigators did see signs of hypoplasia, in example fewer
ethmoid cells. This observation was in concordance with data
from Eggesbo and colleagues (20).
Osteitis/neoosteogenesis in patients with rhinosinusitis is
associated with increased severity of inflammation (25). The
extent of osteitis has been correlated with the Lund–Mackay score,
duration of symptoms and previous surgery (26). Our findings that
patients with class I–III mutations showed significantly more often
osteitis of the maxillary sinus compared to patients with class IV–
V mutations, could indicate the patients with class I–III mutations
experience increased severity of inflammation in the paranasal
sinuses compared to the class IV–V mutation group.
Although the exact pathogenesis of sinonasal disease is not
entirely clarified, one could speculate on a rationale for the
sinonasal phenotype to be affected by CFTR genotype. One
explanation could be that class I–III mutations result in higher
viscosity of the sinonasal mucus and therefore rhinosinusitis is
more easily developed compared to class IV–V mutations.
Furthermore, the sinonasal system could be directly related to
the function of the CFTR protein at the apical membrane of the
sinonasal mucosa. Wang and co-workers (2) showed that carriersof a CFTR mutation are predisposed to develop chronic rhino-
sinusitis compared to the normal wild-type CFTR population.
Previous research showed that heterozygote carriers of CFTR
mutations have approximately 50% of the normal CFTR function
compared to wild-type CFTR, which is sufficient to remain free of
disease (27). Patients with class IV–Vmutations have a decreased
CFTR function, but they often have residual CFTR function. This
residual function could result in sinonasal disease, but not as
severe as in patients with no CFTR function, such as patients with
class I–III mutations. Thus, CFTR function could be directly
related to the development of rhinosinusitis.
To our knowledge, this is the first study to describe the
specific abnormal anatomy of the uncinate process in patients
with CF. Previously, medial bulging of the lateral nasal wall,
aplasia/hypoplasia of the uncinate process and demineralization
of the process have been observed in CF patients (23,28–31).
According to the investigators this bulging and demineralization
were associated with a maxillary sinus mucocele. Absence or
hypoplasia of the uncinate process may follow maxillary sinus
hypoplasia (32). However, in our study population we did not
find any signs for a maxillary mucocele. Moreover the anatomy
we observed did not resemble hypoplasia. The uncinate process
was projected medially towards the nasal septum, instead of
projected in an upwards direction. Remarkably this anatomy
results in a wide and open infundibulum, which in theory
facilitates good drainage from the sinus to the nasal cavity.
To date, the pathogenesis of sinonasal disease in CF is not
fully elucidated. Research in children with CF is needed to
investigate the beginning of sinonasal disease in CF. The
results of the present study emphasise that rhinosinusitis in CF
patients is chronic, but unfortunately the onset of this extensive
pathology is unknown.
In summary this observational study showed the prevalence
of rhinosinusitis in adult patients with CF was 63% and the
prevalence of nasal polyps was 25%. Patients with class I–III
mutations had significantly smaller frontal sinuses, sphenoid
sinuses, more opacification in the sinonasal area and more often
osteitis/neoosteogenesis of the maxillary sinus wall compared to
patients with class IV–V mutations. Despite this considerable
sinonasal pathology, patients do not estimate these problems as
very troublesome. For this reason the investigators recommend
a regular examination of the sinonasal area in all CF-patients.Funding
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